← Back to Search

Antimicrobial Wound Dressing

Intervention Period for Foot Ulcer

N/A
Waitlist Available
Research Sponsored by Chester Ho, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion over four months
Awards & highlights

Study Summary

This trial evaluates the effectiveness of a new wound dressing, NanoSALV, to improve chronic wound care, cost-savings, patient satisfaction, and healing time. Interviews and observations are used to assess usability.

Eligible Conditions
  • Diabetic Foot Ulcers
  • Pressure Ulcer
  • Leg Ulcer
  • Venous Leg Ulcer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion over four months
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion over four months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Process Improvement
Quality Improvement
Soft Cost Savings
+2 more
Secondary outcome measures
Adverse events
Patient preference
Patient satisfaction - comfort
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention PeriodExperimental Treatment1 Intervention
Patients receive the intervention, NanoSALV wound dressing, in the consecutive four weeks following the control period
Group II: Control PeriodActive Control1 Intervention
Patients receive the current standard of care for their chronic wound in the first four weeks of enrollment Standard of care (SOC) involves: Offloading of pressure as needed High compression bandaging, as needed Debridement, as needed Nutrition management, as needed SOC dressings, such as silver/iodine dressings, antibiotic ointment Management of infection Management of pain during debridement, as needed
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NanoSALV Catalytic
2022
N/A
~50

Find a Location

Who is running the clinical trial?

Chester Ho, MDLead Sponsor
Alberta Health servicesOTHER
158 Previous Clinical Trials
649,625 Total Patients Enrolled
NanoTess Inc.UNKNOWN
~18 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top